Patents
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
04/2011
04/07/2011CA2776143A1 Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
04/06/2011EP2305836A1 Compositions, kits and methods for identification, assessment, prevention and therapy of cervical cancer
04/06/2011EP2305827A1 Cancer antigen MAGE-A9 and uses thereof
04/06/2011EP2305813A2 Fuctional and hyperfunctional sirna
04/06/2011EP2305812A2 Fuctional and hyperfunctional sirna
04/06/2011EP2305805A1 Double-stranded polynucleotide
04/06/2011EP2305795A1 Method of collecting placental stem cells
04/06/2011EP2305709A1 Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof
04/06/2011EP2305699A1 Stabilised mRNA with increased G/C content which is optimised for translation in its coded areas
04/06/2011EP2305353A1 Augmented cognitive training
04/06/2011EP2305315A1 Method for in vivo regulation of cardiac muscle contractility
04/06/2011EP2305302A2 Prevention and treatment of amyloidogenic disease
04/06/2011EP2305299A1 Chimeric alphavirus replicon particles
04/06/2011EP2305291A1 Use of proteasome inhibitors for the treatment of HIV infections
04/06/2011EP2305221A1 Dna damage repair inhibitors for treatment of cancer
04/06/2011EP2304049A1 Method of treatment of vascular complications
04/06/2011EP2304034A1 An adapter molecule for the delivery of adenovirus vectors
04/06/2011EP2303336A2 Sulfonylurea receptor and means for treating ischaemia
04/06/2011EP2303335A1 Method of treating hearing loss using xiap
04/06/2011EP2303334A1 Vector
04/06/2011EP2303319A2 Compositions, methods and kits for eliciting an immune response
04/06/2011EP1599586B1 Rna-interference for znfn3a1-gene as a method for inhibiting cancer cell growth
04/06/2011EP1594889B1 Nell peptide expression systems and bone formation activity of nell peptide
04/06/2011EP1529113B1 Vaccinia virus host range genes to increase the titer of avipoxviruses
04/06/2011EP1411979B1 Vaccine comprising gp120 and nef and/or tat for the immunisation against hiv
04/06/2011EP1291424B1 Gasc1 gene
04/06/2011CN1910284B Epitope/peptide recognized by HLA-A2402-restricted Ep-CAM-specific CTL and use of the same
04/06/2011CN102006891A Continuous cell programming devices
04/06/2011CN102002513A Efficiently-mediated DC gene transfer recombinant adenovirus
04/06/2011CN102002499A shRNA capable of inhibiting replication and infection of Japanese encephalitis virus and application thereof
04/06/2011CN102002493A Application of small RNA-326 in preparation of medicament
04/06/2011CN102002489A MicroRNA for inhibiting multiplication of H1N1 influenza virus and application thereof
04/06/2011CN102002484A Preparation method and application of adenovirus-alphavirus hybrid virus
04/06/2011CN102002483A Hematopoietic targeted helper adenovirus and application thereof
04/06/2011CN102002105A Gene, expression vector, expression method, expression cell and application of human papilloma virus (HPV) 16 E7E6 fusion protein
04/06/2011CN102002102A Body weight modulators, corresponding nucleic acids and proteins, and their use for diagnosis and therapy
04/06/2011CN102000347A Application of microRNA-139
04/06/2011CN102000346A Nanometer nucleic acid guide medicine, and preparation method and application thereof
04/06/2011CN102000330A Nucleic acid vaccine adjuvant and construction method thereof
04/06/2011CN101497652B Peptide for inhibiting solid tumor and leukaemia cancer cell growth and use thereof
04/06/2011CN101429523B Type T non--viral vector and composite medicament containing the same
04/06/2011CN101173282B Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
04/06/2011CN101116747B Cytosine arabinoside and gland correlated virus composite preparations and uses thereof
04/05/2011US7919613 RNAi modulation of SCAP and therapeutic uses thereof
04/05/2011US7919612 Comprises modified nucleotide sequences for use in gene expression inhibition, viral defense, transposon silencing and treatment of metabolic disorders; antisense agents
04/05/2011US7919604 Fetal genes
04/05/2011US7919588 Netrin receptors
04/05/2011US7919478 Using vascular endothelial growth factor as wound healing agent; tissue engineering; regenerative medicine; wound healing agent
04/05/2011US7919476 Modulation of glucagon receptor expression
04/05/2011US7919475 Compositions and methods for improving heart function
04/05/2011US7919474 Gene expression inhibition; sustained release; for reduction of neuronal cell death, inflammation, and scar formation; improves wound healing, skin rejuvenation and thickening
04/05/2011US7919473 IRNA agents targeting VEGF
04/05/2011US7919471 Method of modulating cell survival and reagents useful for same
04/05/2011US7919311 Compositions and methods for activating genes of interest
04/05/2011US7919309 Method for expression of small antiviral RNA molecules within a cell
04/05/2011US7919269 Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
04/05/2011US7919098 ErbB-3 based methods and compositions for treating neoplasms
04/05/2011US7919091 Lipolysis stimulated receptor (LSR) specific antibodies
04/05/2011US7919085 Using secretory carrier membrane protein 5 protein specific monoclonal antibody as diagnostic tool in screening for cutaneous t-cell lymphomas (CTCL)
04/05/2011US7919081 Hydrogenase deficient bacterial strains
04/05/2011US7919080 Immortalized hepatocyte cell line secreting modified insulin with glucose sensitivity
04/05/2011CA2543928C Optimized expression of hpv 58 l1 in yeast
04/05/2011CA2261562C Fusion polypeptides comprising an ige-binding domain and a hsa component, and their diagnostic and therapeutic uses
03/2011
03/31/2011WO2011038210A2 Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
03/31/2011WO2011038205A2 Treatment of growth hormone (gh) related diseases by inhibition of natural antisense transcript to gh
03/31/2011WO2011036487A1 Cancer therapy
03/31/2011WO2010136580A3 Tumour-specific bacterial promoter elements
03/31/2011WO2010117829A3 Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjögren's syndrome
03/31/2011WO2010102058A3 Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
03/31/2011US20110078804 Angiogenin and Amyotrophic Lateral Sclerosis
03/31/2011US20110077287 Pharmaceutical composition containing a stabilised mrna optimised for translation in its coding regions
03/31/2011US20110077203 Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
03/31/2011US20110076773 Delivery of DNA or RNA via gap junctions from host cells to target cells and a cell-based delivery system for antisense or siRNA
03/31/2011US20110076286 Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
03/31/2011US20110076259 Detection of risk of pre-eclampsia
03/31/2011US20110076248 Immunizing compositions comprising hiv-1 proviral constructs with an inactive p6 gag tsg101 uev binding domain capable of producing budding-defective viral particles that remain tethered to the cell surface.
03/31/2011CA2775111A1 Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
03/30/2011EP2302063A2 Intact minicells as vectors for DNA transfer and gene therapy in vitro and in vivo
03/30/2011EP2302039A1 Virus-like particles comprising HML-2 gag polypeptide
03/30/2011EP2301586A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
03/30/2011EP2301585A1 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
03/30/2011EP2301584A1 Methods and compositions for treatment of interferon-resistant tumors
03/30/2011EP2301583A1 Lentiviral vector-mediated gene transfer and uses thereof
03/30/2011EP2301582A1 Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
03/30/2011EP2301573A1 Anti-cancer and anti-infectious disease compositions and methods for using same
03/30/2011EP2301567A1 Selective immune down regulation (SIDR) for transplantation
03/30/2011EP2301566A1 DNA vaccines encoding heat shock proteins
03/30/2011EP2301565A1 Use of proteasome inhibitors for the treatment of viral infections
03/30/2011EP2301560A1 Pharmaceutical agent for promoting the functional regeneration of damaged tissue
03/30/2011EP2301559A1 Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
03/30/2011EP2301553A1 Polynucleotide therapy
03/30/2011EP2301552A1 Polynucleotide therapy
03/30/2011EP2300608A2 Methods to treat solid tumors
03/30/2011EP2300607A2 Method for treating and preventing radiation damage using genetically modified mesenchymal stem cells
03/30/2011EP2300041A2 Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
03/30/2011EP2300023A2 Microorganisms for preventing and treating neoplasms accompanying cellular therapy
03/30/2011EP2299985A1 Diagnostic reagent, containing bioparticles, method for production thereof and use thereof as internal standard in nucleic acid preparation and nucleic acid detection methods
03/30/2011EP1680508B1 Site-specific intestinal delivery and/or production of biologically active substances
03/30/2011EP1337242B1 Gene delivery formulations for treatment of ischemic conditions
03/30/2011EP1317485B1 Myostatin antagonists and uses thereof